Skip to main content
KZIA logo

KZIA · Kazia Therapeutics Ltd · Financials

Track KZIA — free
$8.69 +0.36 (+4.32%)
Market Cap
$129.52M
Shares
15.55M
Volume · Oct 29 76.84K Avg daily vol (3M) 272.2K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
42K -98.2%
FY2025 Revenue FY2016–FY2025
Net Income
-20.7M +22.7%
FY2025 Net Income FY2016–FY2025
Operating Cash Flow
-13.28M -38.6%
FY2025 Operating Cash Flow FY2016–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016
AUD 42K 2.31M 0 0 15.18M — — 119K 249K 406K
AUD 7.33M 17.38M 15.56M 20.17M 14.54M 9.49M 6.48M 9.77M 11.14M 9.89M
AUD 934K 1.87M 1.87M 1.87M — 1.08M 1.08M 1.55M 1.42M 643K
AUD — — — — — — — — 765K —
AUD -22.45M -27.05M -20.74M -25.38M -8.9M -12.77M -10.57M -6.34M -10.87M -12.16M
AUD -1.75M -271K -271K -368K -484K -298K -298K -305K -199K —
AUD -20.7M -26.78M -20.47M -25.01M -8.42M -12.47M -10.27M -6.04M -10.67M -12.06M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2025: 0 in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Short-term borrowings 2025-12-31 AUD 98,807 6-K filed 2026-03-30
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1075880 CUSIP 48669G303 13F (30d) 4 filings 4 filers Visit website Investor relations